Commense Bio is a biopharmaceutical company committed to developing and delivering transformative therapeutics for patients suffering from invasive infections with a significant unmet need. Our proprietary technology has the potential to unlock the next generation of bacterial therapeutics. Commense Bio is utilizing differentiated synthetic biology to engineer optimized bacterial strains and deliver novel therapeutics. Our innovative Safety Switched ™ strains mimic nature and use bacterial interference to prevent invasive infections. At Commense Bio, we are applying our broad IP Platform across multiple infectious diseases as we strive to establish new, transformative standards of care.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Boulder, Co 80301, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Infectious Disease, S. aureus, E. coli, Bacterial Therapeutics, Bacterial Interference, Synthetic Biology, Invasive Infections.
- HQ
- Boulder, CO
Commense Bio Questions
Commense Bio's LinkedIn profile is https://www.linkedin.com/company/commense-bio
Commense Bio has
3 employees.
View email and phone details for 3
employees at Commense Bio.
Commense Bio's industry is
Biotechnology Research
Commense Bio's top competitors are
Yale Ventures,
Vithera Pharmaceuticals, Inc.,
Oxidien Pharmaceuticals,
Commense,
Accendatech Usa,
Renosome Bio,
Edgewise Therapeutics,
Bristol Myers Squibb,
I.e. Advising, Llc,
Commense Ai.
Commense Bio's categories are Biotechnology Research
Commense Bio's founding year is 2016
